Research programme: plectasin antibacterial - Sanofi

Drug Profile

Research programme: plectasin antibacterial - Sanofi

Alternative Names: NZ 2114; Plectasin derivative - Sanofi

Latest Information Update: 22 Jan 2014

Price : $50

At a glance

  • Originator Novozymes A/S
  • Developer Novozymes A/S; Sanofi
  • Class Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 22 Jan 2014 Discontinued - Preclinical for Gram-positive infections in France (IV)
  • 17 Aug 2012 Final pharmacodynamics and pharmacokinetics data from a preclinical study in Gram-positive infections released by sanofi-aventis
  • 27 Oct 2011 Discontinued - Preclinical for Gram-positive infections in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top